Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Results from the first South African Health Products Regulatory Authority-approved randomised trial evaluating supplementation of standard antibiotic therapy with a commercially available probiotic in South African women with bacterial vaginosis

Anna-Ursula Happel, Ravesh Singh, Nireshni Mitchev, Koleka Mlisana, Heather B. Jaspan, Shaun L. Barnabas, Jo-Ann S. Passmore
doi: https://doi.org/10.1101/2020.05.04.20090282
Anna-Ursula Happel
1Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: anna.happel@uct.ac.za
Ravesh Singh
2School of Laboratory Medicine and Medical Sciences, University of Kwa-Zulu Natal, Durban, South Africa
3National Health Laboratory Service, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nireshni Mitchev
2School of Laboratory Medicine and Medical Sciences, University of Kwa-Zulu Natal, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koleka Mlisana
2School of Laboratory Medicine and Medical Sciences, University of Kwa-Zulu Natal, Durban, South Africa
3National Health Laboratory Service, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather B. Jaspan
1Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
4Seattle Children’s Hospital, Seattle, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaun L. Barnabas
1Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
5Family Clinic Research Unit, Stellenbosch University, Tygerberg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jo-Ann S. Passmore
1Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
3National Health Laboratory Service, South Africa
6NRF-DST CAPRISA Centre of Excellence in HIV Prevention, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Abstract

Background Bacterial vaginosis (BV) increases HIV risk and adverse reproductive outcomes in women. The standard-of-care (SOC) for BV is antibiotic treatment; however, cure rates are low and recurrence frequent. In South Africa, no trial comparing probiotics to SOC for BV has been approved by the South African Health Products regulatory Authority (SAHPRA). We aimed to explore the South African regulatory and ethics environment to evaluate adjunctive probiotics for improvement of BV treatment in a randomized single-blinded trial of a locally sourced oral-vaginal-combination probiotic for vaginal health.

Methods South African women with symptomatic vaginal discharge were screened for BV and sexually transmitted infections (STIs) including Trichomonas vaginalis, Mycoplasma genitalium, Neisseria gonorrhoae and Chlamydia trachomatis. BV positive (by Nugent Scoring) STI negative women were randomized to Metrogel™ alone (n=12) or Metrogel™ followed by a commercially available South African oral/vaginal probiotic (Vagiforte PLUS® Combo Pack; n=18). BV cure at one month was the primary endpoint. Secondary endpoints were recurrence, symptoms, vaginal microbiota and genital inflammation over five months post-treatment, and acceptability of the administered probiotic.

Results SAHPRA reviewed and acknowledged this trial. Overall, 44.8% of women cleared BV one month post-treatment. Despite confirmed viability of probiotic species contained in the commercial oral/vaginal probiotic, they did not appear to colonize the female genital tract of most women in the intervention group. No significant differences in BV cure rates, vaginal pH, microbiota nor IL-1α concentrations were found between SOC and intervention groups, although we were underpowered to detect small differences. Acceptability and adherence to the probiotic product was high.

Conclusion Navigation of the SAHPRA registration process for evaluating a commercial probiotic in a randomised trial has laid the path for future trials of improved probiotic products for vaginal health in South Africa with adequate sample sizes. Acceptability of vaginally applied probiotics was high in South African women. Improvements in both the content and delivery of commercially available probiotic products for vaginal health should be considered.

Trial registration This trial was registered on 17 October 2017 with the South African National Clinical Trial Register of the Department of Health (DOH-27-1117-5579).

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

DOH-27-1117-5579

Funding Statement

The study was funded by DST-NRF CAPRISA Centre of Excellence in HIV Prevention (PI: J. Passmore). AUH received bursaries from the South African Poliomyelitis Research Foundation and National Research Foundation during her PhD, and Postgraduate Publication Incentive funding from the University of Cape Town. The funders had no role the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 08, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Results from the first South African Health Products Regulatory Authority-approved randomised trial evaluating supplementation of standard antibiotic therapy with a commercially available probiotic in South African women with bacterial vaginosis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Results from the first South African Health Products Regulatory Authority-approved randomised trial evaluating supplementation of standard antibiotic therapy with a commercially available probiotic in South African women with bacterial vaginosis
Anna-Ursula Happel, Ravesh Singh, Nireshni Mitchev, Koleka Mlisana, Heather B. Jaspan, Shaun L. Barnabas, Jo-Ann S. Passmore
medRxiv 2020.05.04.20090282; doi: https://doi.org/10.1101/2020.05.04.20090282
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Results from the first South African Health Products Regulatory Authority-approved randomised trial evaluating supplementation of standard antibiotic therapy with a commercially available probiotic in South African women with bacterial vaginosis
Anna-Ursula Happel, Ravesh Singh, Nireshni Mitchev, Koleka Mlisana, Heather B. Jaspan, Shaun L. Barnabas, Jo-Ann S. Passmore
medRxiv 2020.05.04.20090282; doi: https://doi.org/10.1101/2020.05.04.20090282

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Sexual and Reproductive Health
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (50)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5219)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (750)
  • Geriatric Medicine (77)
  • Health Economics (212)
  • Health Informatics (694)
  • Health Policy (352)
  • Health Systems and Quality Improvement (223)
  • Hematology (99)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5823)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (758)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (94)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (139)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (854)
  • Public and Global Health (1995)
  • Radiology and Imaging (345)
  • Rehabilitation Medicine and Physical Therapy (157)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)